Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 9/12/16 → 9/11/18 |
Funding
- Neuraltus Pharmaceuticals Incorporated: $148,811.00
NP001: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
- Kasarskis, Edward (PI)